Key result
Balloon aortic valvuloplasty carries low intraprocedural risk, with death occurring in ~2% of patients.
Why the study?
The role and indications of balloon aortic valvuloplasty (BAV) in the era of transcatheter aortic valve replacement (TAVR) remain to be clearly defined despite advances in TAVR technology and technique.
May support BAV as safe adjunct in select TAVR cases; leaves optimal role and long-term outcomes open.
Cribier et al1 first described the use of balloon aortic valvuloplasty (BAV) to treat 3 elderly patients with severe calcific aortic stenosis (AS) in 1986. All patients survived the procedure with significant reductions in valve gradients and improvements in symptoms.
No takes yet. Share an insight, caveat, or question.
Garcia et al. (2023) conducted an editorial in Severe calcific aortic stenosis (n=14,300). Balloon aortic valvuloplasty (BAV) was evaluated on Serious intraprocedural complications (death, stroke, and vascular complications). A pooled analysis of 14,300 patients treated with balloon aortic valvuloplasty demonstrated low rates of serious intraprocedural complications, including 1.9% for death, 1.2% for stroke, and 4.7% for vascular complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: